Updates are available Correction dated 2023-07-17
Click to view Correction: https://doi.org/10.1038/s41541-023-00703-0
-
Authors
Kim, Changyoun
Hovakimyan, Armine
Zagorski, Karen
Antonyan, Tatevik
Petrushina, Irina
Davtyan, Hayk https://orcid.org/0000-0001-8554-6456
Chailyan, Gor
Hasselmann, Jonathan
Iba, Michiyo
Adame, Anthony
Rockenstein, Edward
Szabo, Marcell https://orcid.org/0000-0002-1336-1951
Blurton-Jones, Mathew https://orcid.org/0000-0002-7770-7157
Cribbs, David H.
Ghochikyan, Anahit
Masliah, Eliezer
Agadjanyan, Michael G. https://orcid.org/0000-0002-9602-0406
- License Information
-
More Information
Article History
Received: 26 July 2021
Accepted: 24 November 2021
First Online: 10 January 2022
Change Date: 15 October 2024
Change Type: Update
Change Details: Editor's Note: Readers are alerted that concerns have been raised regarding the reliability of data presented in this article. Further editorial action will be taken if appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.
Change Date: 17 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41541-023-00703-0
Change Date: 12 March 2025
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1038/s41541-025-01102-3
Competing interests
: M.G.A. and A.G. are co-founders of Nuravax that licensed MultiTEP vaccine platform technology from the Institute for Molecular Medicine. The remaining authors declare that they have no competing interests.
